CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ — Insilico Medicine (“Insilico”), a global leader in AI-powered drug discovery, and Atossa Therapeutics (“Atossa”) (Nasdaq: ATOS), a…
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
